Laekna (HKG:2105) said it began recruitment for its Phase I multiple-ascending dose study in China for its obesity drug, with the first visit of the first subject completed, according to a filing with the Hong Kong bourse on Wednesday.
LAE102 is a monoclonal antibody targeting ActRIIA, a receptor linked to muscle growth and fat metabolism, and has been shown to increase muscle and reduce fat in pre-clinical tests.
The pharmaceutical's shares were up by about 11% in recent trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。